Treatment options for malignant pleural effusions: Patient preference does matter

JAMA

Volumn 307, Issue 22, 2012, Pages 2432-2433

  Maskell, Nick A ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ASPIRATION; CLINICAL EFFECTIVENESS; DYSPNEA; EDITORIAL; HEALTH CARE PRACTICE; HUMAN; MEDICAL DECISION MAKING; PATIENT CARE; PATIENT PREFERENCE; PLEURA CANCER; PLEURA EFFUSION; PLEURODESIS; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; THERAPY EFFECT; THORAX DRAINAGE; TREATMENT PLANNING; CATHETERIZATION; FEMALE; MALE; METHODOLOGY; NOTE;

TALC;

CATHETERIZATION; DYSPNEA; FEMALE; HUMANS; MALE; PLEURAL EFFUSION, MALIGNANT; PLEURODESIS; TALC;

EID: 84862249630     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2012.5543     Document Type: Editorial

References (14)

1. Haas AR, Sterman DH, Musani AI. Malignant pleural effusions. Chest. 2007;132:1036-1041.
2. Roberts ME, Neville E, Berrisford RG, Antunes G, Ali NJ; BTS Pleural Disease Guideline Group. Management of a malignant pleural effusion: British Thoracic Society Pleural Disease Guideline 2010. Thorax. 2010;65(suppl 2):ii32-ii40.
3. Musani AI, Haas AR, Seijo L, Wilby M, Sterman DH. Outpatient management of malignant pleural effusions with small-bore, tunneled pleural catheters. Respiration. 2004;71(6):559-566. (Pubitemid 40091427)
4. Burrows CM, Mathews WC, Colt HG. Predicting survival in patients with recurrent symptomatic malignant pleural effusions: an assessment of the prognostic values of physiologic, morphologic, and quality of life measures of extent of disease. Chest. 2000;117(1):73-78. (Pubitemid 30053623)
5. Tan C, Sedrakyan A, Browne J, Swift S, Treasure T. The evidence on the effectiveness of management for malignant pleural effusion: a systematic review. Eur J Cardiothorac Surg. 2006;29(5):829-838.
6. Maskell NA, Lee YC, Gleeson FV, Hedley EL, Pengelly G, Davies RJ. Randomized trials describing lung inflammation after pleurodesis with talc of varying particle size. Am J Respir Crit Care Med. 2004;170(4):377-382. (Pubitemid 39214610)
7. Dresler CM, Olak J, Herndon JE II, et al; Cooperative Groups Cancer and Leukemia Group B; Eastern Cooperative Oncology Group; North Central Cooperative Oncology Group; Radiation Therapy Oncology Group. Phase III intergroup study of talc poudrage vs talc slurry sclerosis for malignant pleural effusion. Chest. 2005;127(3):909-915.
8. Hooper C, Maskell N; BTS audit team. British Thoracic Society national pleural procedures audit 2010. Thorax. 2011;66(7):636-637.
9. Van Meter ME, McKee KY, Kohlwes RJ. Efficacy and safety of tunneled pleural catheters in adults with malignant pleural effusions: a systematic review. J Gen Intern Med. 2011;26(1):70-76.
10. Olden AM, Holloway R. Treatment of malignant pleural effusion: PleuRx catheter or talc pleurodesis? a cost-effectiveness analysis. J Palliat Med. 2010;13(1):59-65.
11. Putnam JB Jr, Light RW, Rodriguez RM, et al. A randomized comparison of indwelling pleural catheter and doxycycline pleurodesis in the management of malignant pleural effusions. Cancer. 1999;86(10):1992-1999.
12. Davies HE, Mishra EK, Kahan BC, et al. Effect of an indwelling pleural catheter vs chest tube and talc pleurodesis for relieving dyspnea in patients with malignant pleural effusion: the TIME2 randomized controlled trial [published online May 20, 2012]. JAMA. 2012;307(22):2383-2389.
13. Wyckoff CC, Anderson ED, Read CA, Lee RE. The use of intrapleural doxycycline via PleuRx catheter in the treatment of malignant pleural disease: preliminary report. Chest. 2007;132:432S.
14. Terra RM, Kim SY, Pego-Fernandes PM, Teixeira LR, Vargas FS, Jatene FB. Is silver nitrate pleurodesis for patients with malignant pleural effusion feasible and safe when performed in an outpatient setting? Ann Surg Oncol. 2011;18(4):1145-1150.